une 5, 2015
The American Society of Clinical Oncology has its big meeting each year in Chicago in early June. In the past solid tumor cancers have received the most attention, saving blood cancer announcements for the American Society of Hematology meeting where the focus is more narrow. This year, however, was different, with big news coming from Baxter/CTIBiopharma on their Pacritinib data. Dr. Ruben Mesa presented at a press conference on progress for this drug, which is intended for people with myelofibrosis who have low platelet counts. There was also news on allogenic stem cell transplant for MF. Below are reports on presentations made during this conference:
Allogeneic transplantation for myelofibrosis: Final analysis of a prospective study after a median follow up of 5 years.
ASCO 2015: JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis
An ASCO Primer: Which Drug Makers are Pursuing Which Kinds of Therapies